Centre Amends Rules To Add Suspension And Cancellation Of License Provisions On Imported Medical Devices

New Delhi : The Union ministry of health and family welfare (MoHFW) has notified amendment of Medical Devices Rules, 2017, to incorporate provisions for suspension and cancellation of import license as part of its efforts to implement improved regulations on the medical devices in the country.

The Medical Devices (Third Amendment) Rules, 2022, inserts a new Rule after the Rule 43, which is related to import of medical devices for personal use. Named as Rule 43 A, it deals with the suspension and cancellation of license and has come into force on the date of its publication in the Official Gazette, which was on May 18, 2022.

According to the new rule, if the manufacturer or licensee fails to comply with any of the conditions of an import license, or any provisions of the Act and those rules, the Central Licensing Authority (CLA) may after giving the manufacturer or licensee an opportunity to show cause why such an order should not be passed, by an order in writing stating the reason, cancel the license issued under the rules or suspend it for such a period as it thinks fit either wholly or in respect of any of the part of medical device to which it relates.

Under the Rule, the Authority can also direct the licensee to stop import, sale or distribution of the said medical device and order the destruction of medical device and stock in presence of officer authorised by the CLA, if in its opinion, the licensee has failed to comply with any of the conditions of the license or with any provisions of the Act or Rules.

However, it also added a provision under which the person aggrieved by the order passed by the CLA under the rule, may file an appeal to the Central Government within 30 days of the serving of the order. The Central Government may, after such enquiry into the matter, as it considers necessary and after giving the appellant an opportunity for hearing, pass such order as it thinks fit, it added.

A draft notification towards this was published on January 19, 2022, for the information of all persons likely to be affected. It had also issued a notice that the said draft rule shall be taken into consideration or after the expiry of a period of fourth-five days from the date on which the copies of the Gazette of India these draft rules are made available to the public.

Following the publication of the draft, the Central Government has considered the objections and suggestions received from the public.

The MoHFW has been bringing in rules and amendments into the medical devices sector, both in terms of imported products and in terms of India devices, including classification of all medical devices into four classes based on their risk level. Following this, these medical devices will be brought under license regime in a fixed timeframe based on the classification.

  • Related Posts

    • Pharma
    • May 30, 2024
    • 59 views
    BRICS Vaccine Research Center Launched In India

    New Delhi: In a statement issued after the meeting, Union Health Secretary Apurva Chandra said that the BRICS Vaccine Research and Development Centre, established during India’s BRICS presidency, was dedicated to…

    • Pharma
    • May 29, 2024
    • 59 views
    DCA seizes ayurvedic syrup over false claims

    Hyderabad: The Drugs Control Administration (DCA) Telangana conducted raids on shops selling products with misleading advertisements and seized an ayurvedic medicine in Kothur village. The medicine labelled as ‘stone crush…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    BRICS Vaccine Research Center Launched In India

    BRICS Vaccine Research Center Launched In India

    DCA seizes ayurvedic syrup over false claims

    DCA seizes ayurvedic syrup over false claims

    Delhi Police Busts Major Illegal Alprazolam Manufacturing Racket

    Delhi Police Busts Major Illegal Alprazolam Manufacturing Racket

    Ajooni Biotech expects additional revenue of Rs 200 crore from commercial production of Moringa by FY 25-26

    Ajooni Biotech expects additional revenue of Rs 200 crore from commercial production of Moringa by FY 25-26

    BackBack Natco Pharma share price rises 8% to 52 week high post Q4 results

    BackBack Natco Pharma share price rises 8% to 52 week high post Q4 results

    Human Milk Siphoned Off From Banks To Industries

    Human Milk Siphoned Off From Banks To Industries